First Light Asset Management LLC reduced its stake in shares of Teligent Inc (NASDAQ:TLGT) by 26.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,100,823 shares of the company’s stock after selling 402,304 shares during the period. First Light Asset Management LLC owned approximately 2.06% of Teligent worth $3,699,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of TLGT. Schwab Charles Investment Management Inc. boosted its position in shares of Teligent by 26.1% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 74,300 shares of the company’s stock worth $270,000 after purchasing an additional 15,400 shares in the last quarter. UBS Asset Management Americas Inc. boosted its position in shares of Teligent by 282.7% during the 4th quarter. UBS Asset Management Americas Inc. now owns 51,034 shares of the company’s stock worth $185,000 after purchasing an additional 37,700 shares in the last quarter. Broadfin Capital LLC boosted its position in shares of Teligent by 35.1% during the 4th quarter. Broadfin Capital LLC now owns 1,925,415 shares of the company’s stock worth $6,989,000 after purchasing an additional 500,000 shares in the last quarter. Deutsche Bank AG boosted its position in shares of Teligent by 82.5% during the 4th quarter. Deutsche Bank AG now owns 90,938 shares of the company’s stock worth $329,000 after purchasing an additional 41,119 shares in the last quarter. Finally, Guggenheim Capital LLC boosted its position in shares of Teligent by 86.6% during the 4th quarter. Guggenheim Capital LLC now owns 352,934 shares of the company’s stock worth $1,281,000 after purchasing an additional 163,817 shares in the last quarter. Institutional investors own 62.10% of the company’s stock.

Several equities research analysts have commented on TLGT shares. Canaccord Genuity decreased their target price on shares of Teligent from $4.00 to $3.50 and set a “hold” rating on the stock in a research report on Friday, March 2nd. Zacks Investment Research upgraded shares of Teligent from a “sell” rating to a “hold” rating in a research report on Tuesday, March 13th. Finally, ValuEngine upgraded shares of Teligent from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $7.00.

Shares of Teligent opened at $3.90 on Thursday, according to MarketBeat.com. The firm has a market cap of $172.31 million, a price-to-earnings ratio of -17.21 and a beta of 0.77. Teligent Inc has a one year low of $2.43 and a one year high of $9.54. The company has a debt-to-equity ratio of 3.07, a quick ratio of 1.69 and a current ratio of 2.73.

Teligent (NASDAQ:TLGT) last released its quarterly earnings results on Tuesday, May 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.01). The firm had revenue of $14.55 million for the quarter, compared to analyst estimates of $15.62 million. Teligent had a negative return on equity of 27.25% and a negative net margin of 28.98%. analysts forecast that Teligent Inc will post -0.06 EPS for the current year.

Teligent Company Profile

Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.

Institutional Ownership by Quarter for Teligent (NASDAQ:TLGT)

Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.